CN111888463A - Thymosin beta 4 medicinal preparation for treating depression, preparation method and application thereof - Google Patents
Thymosin beta 4 medicinal preparation for treating depression, preparation method and application thereof Download PDFInfo
- Publication number
- CN111888463A CN111888463A CN202010830592.5A CN202010830592A CN111888463A CN 111888463 A CN111888463 A CN 111888463A CN 202010830592 A CN202010830592 A CN 202010830592A CN 111888463 A CN111888463 A CN 111888463A
- Authority
- CN
- China
- Prior art keywords
- thymosin beta
- preparation
- thymosin
- test
- depression
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- UGPMCIBIHRSCBV-XNBOLLIBSA-N Thymosin beta 4 Chemical compound N([C@@H](CC(O)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O)C(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(C)=O UGPMCIBIHRSCBV-XNBOLLIBSA-N 0.000 title claims abstract description 61
- 102100035000 Thymosin beta-4 Human genes 0.000 title claims abstract description 38
- 108010079996 thymosin beta(4) Proteins 0.000 title claims abstract description 38
- 238000002360 preparation method Methods 0.000 title claims abstract description 23
- 238000012360 testing method Methods 0.000 claims abstract description 41
- 230000003997 social interaction Effects 0.000 claims abstract description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 17
- 230000001684 chronic effect Effects 0.000 claims abstract description 16
- 239000000725 suspension Substances 0.000 claims abstract description 11
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 21
- 238000000034 method Methods 0.000 claims description 14
- 241000124008 Mammalia Species 0.000 claims description 13
- 230000006399 behavior Effects 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 10
- 239000002953 phosphate buffered saline Substances 0.000 claims description 10
- 239000000463 material Substances 0.000 claims description 7
- 239000007788 liquid Substances 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 238000012216 screening Methods 0.000 claims description 4
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical group P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 claims description 3
- 230000007357 depressive behavior Effects 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- 208000020401 Depressive disease Diseases 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 101710202766 Thymosin beta-4 Proteins 0.000 abstract description 18
- 230000035882 stress Effects 0.000 abstract description 10
- 230000007267 depressive like behavior Effects 0.000 abstract description 6
- 230000001430 anti-depressive effect Effects 0.000 abstract description 4
- 241000282414 Homo sapiens Species 0.000 abstract description 3
- 230000002441 reversible effect Effects 0.000 abstract description 3
- 208000034656 Contusions Diseases 0.000 abstract description 2
- 238000009227 behaviour therapy Methods 0.000 abstract description 2
- 230000009519 contusion Effects 0.000 abstract description 2
- 201000010099 disease Diseases 0.000 abstract description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 2
- 230000037326 chronic stress Effects 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 39
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 21
- 208000036993 Frustration Diseases 0.000 description 17
- 208000020016 psychiatric disease Diseases 0.000 description 10
- 241000700159 Rattus Species 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 8
- 229930006000 Sucrose Natural products 0.000 description 8
- 230000000994 depressogenic effect Effects 0.000 description 8
- 239000005720 sucrose Substances 0.000 description 8
- 230000035622 drinking Effects 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 238000010586 diagram Methods 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 238000007634 remodeling Methods 0.000 description 4
- 239000008399 tap water Substances 0.000 description 4
- 235000020679 tap water Nutrition 0.000 description 4
- 230000000694 effects Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000008439 repair process Effects 0.000 description 3
- 208000007415 Anhedonia Diseases 0.000 description 2
- 208000028389 Nerve injury Diseases 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000000935 antidepressant agent Substances 0.000 description 2
- 230000003542 behavioural effect Effects 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 239000012669 liquid formulation Substances 0.000 description 2
- 230000008764 nerve damage Effects 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 206010001488 Aggression Diseases 0.000 description 1
- 206010010144 Completed suicide Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010022524 Intentional self-injury Diseases 0.000 description 1
- 241000581650 Ivesia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 101000644414 Rattus norvegicus Thymosin beta-4 Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 208000005560 Self Mutilation Diseases 0.000 description 1
- 206010041247 Social fear Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 108010046075 Thymosin Proteins 0.000 description 1
- 102000007501 Thymosin Human genes 0.000 description 1
- 208000030886 Traumatic Brain injury Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000016571 aggressive behavior Effects 0.000 description 1
- 208000012761 aggressive behavior Diseases 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000008503 anti depressant like effect Effects 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 239000000164 antipsychotic agent Substances 0.000 description 1
- 229940005529 antipsychotics Drugs 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 230000000949 anxiolytic effect Effects 0.000 description 1
- 229940005530 anxiolytics Drugs 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000011748 cell maturation Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000034756 hair follicle development Effects 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 239000004050 mood stabilizer Substances 0.000 description 1
- 229940127237 mood stabilizer Drugs 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 210000005155 neural progenitor cell Anatomy 0.000 description 1
- 230000007658 neurological function Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 230000004799 sedative–hypnotic effect Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 230000011273 social behavior Effects 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- LCJVIYPJPCBWKS-NXPQJCNCSA-N thymosin Chemical compound SC[C@@H](N)C(=O)N[C@H](CO)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CO)C(=O)N[C@H](CO)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@H]([C@H](C)O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@H](CCC(O)=O)C(O)=O LCJVIYPJPCBWKS-NXPQJCNCSA-N 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 230000009529 traumatic brain injury Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2292—Thymosin; Related peptides
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/16—Devices for psychotechnics; Testing reaction times ; Devices for evaluating the psychological state
- A61B5/165—Evaluating the state of mind, e.g. depression, anxiety
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/20—Animals treated with compounds which are neither proteins nor nucleic acids
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/035—Animal model for multifactorial diseases
- A01K2267/0356—Animal model for processes and diseases of the central nervous system, e.g. stress, learning, schizophrenia, pain, epilepsy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B2503/00—Evaluating a particular growth phase or type of persons or animals
- A61B2503/40—Animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B2503/00—Evaluating a particular growth phase or type of persons or animals
- A61B2503/42—Evaluating a particular growth phase or type of persons or animals for laboratory research
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Psychiatry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Environmental Sciences (AREA)
- Zoology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Gastroenterology & Hepatology (AREA)
- Psychology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Child & Adolescent Psychology (AREA)
- Developmental Disabilities (AREA)
- Educational Technology (AREA)
- Hospice & Palliative Care (AREA)
- Organic Chemistry (AREA)
- Social Psychology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Surgery (AREA)
- Animal Husbandry (AREA)
Abstract
The invention discloses a thymosin beta 4 medicinal preparation for treating depression, a preparation method and application thereof, and belongs to the technical field of disease treatment. The invention mainly induces the mouse depression-like behavior by establishing a chronic social contusion stress model (CSDS), and the model has the advantages that the model simulates the social attributes in human chronic stress, and after the model is nasally administered with T beta 4 for 7 consecutive days, the depression level is evaluated by the behavioral tests such as Social Interaction Test (SIT), Tail Suspension Test (TST), sugar water preference test (SPT) and the like, and the result shows that the T beta 4 has the rapid antidepressant effect in the mouse and can reverse the CSDS-induced depression-like behavior within 7 days.
Description
Technical Field
The invention relates to a new application of a peptide substance, belongs to the technical field of disease treatment, and particularly relates to a thymosin beta 4 pharmaceutical preparation for treating depression, a preparation method and an application thereof.
Background
The main indications of mental disease are the obvious and persistent abnormalities of cognitive, emotional, will and behavioral manifestations of the patient, which are difficult to be accepted by society in routine, and the serious impairment of social and mental functions, which can not maintain normal learning, work and life. Under the control of pathological cognition and emotion, aggressive behavior, self-mutilation or suicide can occur. Mental disorders have become a significant medical and social problem in today's society.
Clinically, drugs are the main means and method for the treatment of mental disorders. The mental disease treatment drugs mainly comprise antipsychotics, antidepressants, anxiolytics, mood stabilizers, sedative hypnotics and the like. The research and development of modern mental disease treatment drugs depend on the establishment of mental disease animal models, so that the research and establishment of new test methods and animal models can promote the development and application of mental disease drug treatment, strengthen the understanding of relevant mental disease pathogenesis, improve clinical treatment effects and improve prognosis and outcome. The existing treatment methods for depression mainly comprise traditional Chinese medicine treatment and western medicine treatment, but have the defects of long treatment course, multiple side effects and the like.
Recombinant human/murine/rat thymosin beta 4 is a 5.2kDa glycoprotein containing 45 amino acid residues. Can stimulate the stem cell maturation of central nervous system and improve the neurological function obviously. Thymosin beta 4(T beta 4) has multiple biological functions, and is closely related to tissue regeneration, remodeling, wound healing, actin balance maintenance, apoptosis, inflammation, vascular balance, hair follicle development, cornea and cardiac muscle repair. T β 4 promotes remodeling following CNS/PNS nerve injury. In the chronic phase following nerve injury or the appearance of clinical symptoms, T β 4 promotes neurovascular remodeling. Tss 4 is expressed in neural progenitor cells, is a neural repair molecule with neural repair function, and is involved in cell proliferation, migration, angiogenesis and axon remodeling. It has been found to be effective in reducing stroke, traumatic brain injury and multiple sclerosis models with recovery of lesion volume and function. However, no studies have reported the antidepressant effect of T β 4.
Disclosure of Invention
In order to solve the problems of long treatment course, large side effect and the like of the existing antidepressant drugs, the invention discloses a thymosin beta 4 pharmaceutical preparation for treating depression, a preparation method and application thereof, and researches show that the behavior of mental diseases induced by a subject through a chronic social frustration stress model is reversed after a certain dose of the thymosin beta 4-containing pharmaceutical preparation is taken.
In order to achieve the purpose, the invention discloses a thymosin beta 4 pharmaceutical preparation for treating depression, which comprises effective dose of thymosin beta 4 and a carrier, wherein the carrier is one or two or more than two mixed auxiliary materials, and each 100 parts by mass of the pharmaceutical preparation comprises 12-48 parts by mass of thymosin beta 4, and the balance of the auxiliary materials.
Furthermore, each 100 mass parts of the pharmaceutical preparation comprise 20-40 mass parts of thymosin beta 4.
Further, the auxiliary material is phosphate buffered saline solution.
Further, the pharmaceutical preparation is a liquid preparation, and preferably contains thymosin β 4 in an amount of 30 parts by mass per 100 parts by mass of the liquid preparation.
In addition, the invention also discloses a preparation method of the pharmaceutical preparation, which comprises the steps of blending thymosin beta 4 and a carrier and preparing the required preparation. Preferably, the liquid formulation is prepared according to the invention.
In order to better realize the technical purpose of the invention, the invention also discloses the application of the pharmaceutical preparation in preparing drugs for treating the depression of mammals.
Further, specifically, the method comprises the step of nasally administering a pharmaceutical preparation containing thymosin beta 4 to a mammalian subject, wherein the administration amount is as follows: 12-48 mg thymosin beta 4 per day for 7 consecutive days;
the tested mammal is obtained by screening through establishing a chronic social frustration stress model.
Further, the method comprises the step of comparing the experimental behaviors of the mammal to be tested before and after administration to evaluate the drug effect of the thymosin beta 4-containing drug preparation;
after 7 days of continuous administration, the behavior of the subject mammal was reversed in depression induced by a model of chronic social frustration stress.
Further, the experimental behavior for evaluating the mammalian body to be tested includes one or any two or more of social interaction experiment, tail suspension experiment and sugar water preference experiment.
Further, the subject mammal is a mouse.
Has the advantages that:
the invention induces the depression-like behavior of the mouse by establishing a chronic social frustration emergency model (CSDS). Evaluating the depression level through the behavioral tests such as Social Interaction Test (SIT), Tail Suspension Test (TST), sugar water preference test (SPT) and the like, screening out depressed rats, randomly dividing the rats into a PBS group, 12mg/kg T beta 4, 24mg/kg T beta 4 and 48mg/kg T beta 4(n is 8-10), carrying out nasal administration for 7 days every day, carrying out social behavior tests on the 1 st, 3 th and 7 th days, and simultaneously carrying out tail suspension and sugar water preference tests on the 7 th day to evaluate the depression level. As a result, T β 4 was nasally administered without significantly increasing the residence time in the social area after day 1 compared to PBS administration; after day 3, 24mg/kg and 48mg/kg T β 4 administration significantly increased social residence time (24mg/kg T β 4 group: P <0.05, 48mg/kg T β 4 group: P < 0.01); after day 7, nasal administration of multiple doses of tss 4(12mg/kg, 24mg/kg, 48mg/kg) all showed antidepressant-like effects, i.e. significantly increased residence time in social area (P <0.01), the 48mg/kg tss 4 group significantly decreased immobility time in TST (P <0.01), improved reduction of sugar water preference rate (P < 0.01). Therefore, the thymosin beta 4-containing pharmaceutical preparation designed by the invention has a rapid antidepressant effect in mice, and can reverse CSDS-induced depressive behavior within 7 days.
Drawings
FIG. 1 is a schematic diagram of a social interaction site and a chronic social frustration process, wherein FIG. 1A is the social interaction site and FIG. 1B is the chronic social frustration process;
FIG. 2 is a graph of depressed rat results obtained after the chronic social frustration stress model of the present invention;
FIG. 3 is a diagram of social interaction trajectories after a model of chronic social frustration stress in accordance with the present invention, wherein
FIG. 3A is a diagram of a depression group social interaction trajectory; FIG. 3B is a diagram of resistant group social interaction trajectories;
FIG. 4 is a graph of the analysis of social interaction results after different doses of Tss 4 were administered continuously for different periods of time according to the present invention, wherein FIG. 4A is after 1 day of administration, FIG. 4B is after 3 days of continuous administration, and FIG. 4C is after 7 days of continuous administration;
FIG. 5 is a graph of the percent time to failure of tail suspension after 7 days of continuous administration of Tss 4 at various doses as contemplated by the present invention; wherein, fig. 5A is a schematic view of mouse tail suspension, and fig. 5B is a test result;
figure 6 is a graph of the results of the carbohydrate preference test following 7 days of continuous administration of different doses of tss 4 designed according to the present invention.
Detailed Description
The invention discloses a thymosin beta 4 medicinal preparation for treating depression, a preparation method and application thereof, and particularly relates to a thymosin beta 4-containing medicinal preparation for evaluating the medicinal effect of the thymosin beta 4-containing medicinal preparation by establishing a chronic social frustration emergency model to induce depression-like behaviors of a subject and carrying out experimental behaviors of the subject before and after administration. The results found that the behavior of the subject in mental illness induced by the acute model of chronic social frustration was reversed.
The invention discloses a thymosin beta 4 medicinal preparation for treating depression, which comprises thymosin beta 4 with effective dose and a carrier, wherein the carrier is one or two or more than two auxiliary materials, each 100 parts by mass of the medicinal preparation comprises 12-48 parts by mass of thymosin beta 4, and the balance is the auxiliary materials. Preferably, the thymosin beta 4 is contained in an amount of 20-40 parts by mass per 100 parts by mass of the pharmaceutical preparation.
Wherein the carrier is phosphate buffer saline solution, and the pharmaceutical preparation is in the form of liquid. And further preferably contains thymosin beta 4 in an amount of 30 parts by mass per 100 parts by mass of the liquid preparation.
The pharmaceutical formulations contemplated by the present invention may be conveniently prepared in unit dosage form and using any of the methods well known in the art of pharmacy. Specifically, the active compound thymosin ss 4 is homogeneously and intimately admixed with phosphate buffered saline and formulated into the desired liquid formulation.
Secondly, the pharmaceutical preparation prepared by the invention has better application in the preparation of the drugs for treating the depression of mammals.
In order to better explain the present invention, the following further through each embodiment detailed description of the specific experimental process;
example 1-depressed mice were obtained by chronic social frustration stress experiments;
the embodiment obtains the mouse with the depression-like behavior by establishing a chronic social frustration stress model (CSDS), the model can simulate the depression of human beings caused by frustration in social life, and the model has the advantages of strong repeatability, easiness in operation and the like. The specific model building process is as follows:
1. 6-week-old C57BL/6J mice were randomly divided into test and control groups. For the test group of mice, the CSDS phase lasted for 10 days, carried out daily at the same time period, e.g., 9:00-11:00 in the morning. The test group C57BL/6J mouse is used as an invader to be placed into a 5-month-old male CD-1 mouse cage, so that the mouse is physically attacked for 10min, and the attack duration and effectiveness are ensured.
2. After the frustration treatment was completed, the C57BL/6J and CD-1 mice were separated using a transparent, perforated barrier, ensuring that the C57BL/6J mice were no longer attacked, but were kept in sensory contact, such as olfactory and visual contact, i.e., exposure to social frustration pressure. After 24h, the C57BL/6J mouse was removed and placed in another CD-1 mouse cage, and the procedure described above for step 1 was repeated, and so on. The social interaction site selected by the invention is shown in fig. 1A.
3. Within 10 days, each C57BL/6J mouse in the test group was challenged with a different CD-1 mouse daily and exposed to social frustration pressure, as shown in FIG. 1B. After the end of the last setback treatment, all C57BL/6J mice were housed in a single cage and used for behavioural testing 24h later.
4. The control group C57BL/6J mice were not treated and were fed simultaneously until the CSDS phase was over, and were behaviorally tested together with the test group mice.
All the above procedures ensure that all mice have access to water and food at will.
Example 2-screening of depressed rats;
c57BL/6J mice exposed to social frustration stress for a prolonged period of time develop a socially avoidable depression-like phenotype, in particular, the length of time that a socially frustrated C57BL/6J mouse has been exposed to strange mice is significantly shortened compared to normal C57BL/6J mice over the same period of time. The Social Interaction Test (SIT) can be used to evaluate the social avoidance behavior of mice, which is mainly classified into those in the absence of strange CD1 mice (called the nocarget stage) and those in the presence of strange CD1 mice (called the Target stage), and into CSDS susceptible mice (susceptable) and CSDS resistant mice (resilient) according to the ratio of the lengths of time that C57BL/6J mice enter the social contact area in the two test stages.
1. The social interaction trial was performed 24h after the CSDS process described in example 1 above. The aggressive CD-1 mice need to be rescreened before the test starts and to ensure that the CD-1 mice have no contact and complete strangeness with the C57BL/6J mice tested.
2. And assembling social interaction places, and setting a video tracking system to automatically acquire all data. The tested C57BL/6J mice were acclimated to the test environment, e.g., red light conditions, in advance and isolated from other animals and noise sources.
3. First stage-No Target, C57BL/6J mice were placed in the field of social interaction, such as centered on the opposite side of the pen, allowing them to explore freely for 3min without CD-1 mice. After this phase, the C57BL/6J mice were returned to their primary cages until the second phase, noting that: the social interaction site does not need to be cleaned after the first stage.
4. Second stage-Target, the aggressive CD-1 mice were gently placed into mobile boxes and replaced with the tested C57BL/6J mice, allowing free exploration for 3min in the presence of CD-1 mice, and the manner of placement of the C57BL/6J mice in both stages was consistent.
5. After both phases were completed, the mice were returned to their home cages. And the equipment was sterilized with 75% alcohol before the next round of introduction of a new test C57BL/6J mouse.
6. Calculating the social interaction rate (SI ratio), wherein the mice with the social interaction rate lower than 100 percent belong to CSDS susceptible mice, and the mice with the social interaction rate higher than 100 percent belong to CSDS resistant mice, and the formula is as follows:
as can be seen from FIG. 2, 100C 57BL/6J mice had results of depressed mice and resistant mice obtained after social contusion stress, in which 11 mice died during the challenge, and finally 42 depressed mice and 47 resistant mice were obtained.
As can be seen from FIG. 3, the locus diagrams of depressed rats and resistant rats at no-target and target stages are shown. The residence time of depressed rats in the social area during the target phase is significantly shorter than that of no-target phase, and the opposite is true for resistant rats.
Example 3-thymosin beta 4 was instilled nasally;
tss 4 was dissolved in PBS at concentrations of 30, 60 and 120. mu.g/. mu.L, respectively, and Tss 4 was administered by nasal drip using a 10. mu.L pipette, as needed.
The categories for the selected depressed rats were: CSDS + PBS group (10 μ L PBS, 5 μ L in each nostril), CSDS +12mg/kg T β 4 group (10 μ L PBS, 5 μ L in each nostril); CSDS +24mg/kg Tbeta 4 group is dripped with 10 mu L of 60 mu g/mu L T beta 4, 5 mu L of each nostril; CSDS +48mg/kg Tss 4 group was instilled with 10. mu.L of 120. mu.g/μ L T ss 4, 5. mu.L per nostril.
Example 4-social interaction test to assess depression levels;
social interaction method as shown in example 2, mice given different doses of thymosin T β 4 were tested for social interaction at different times, and the optimal dose and time of administration were then explored. Fig. 4 is a graph of social interaction results after different doses of T β 4 were administered continuously for different periods of time, and it can be seen from fig. 4 that the control group and the T β 4(0, 12, 24 and 48mg/kg T β 4) group with different doses stayed in the social area at different administration conditions for different periods of time, and the results show that 12, 24 and 48mg/kg T β 4 all significantly (P <0.01) improved social fear of mice after the seventh day of administration.
Example 5-tail suspension test to assess depression levels;
the tail suspension test is to induce the "behavior despair state" of the mice by suspending the tail of the mice, and the immobility time of the test mice is recorded to evaluate the depression level thereof.
1. During the test, the tip 1/3 of the test C57BL/6J mouse was taped and suspended in a tail box with the head about 50cm from the bottom and facing the camera. The test is shown in FIG. 5A.
2. The absolute motionless time within 5min after suspension was recorded with a video analysis system.
The test results are shown in fig. 5B. Mice were given Tss 47 days later, the 24mg/kg and 48mg/kg Tss 4 dosing groups showed a significant decrease in percent immobility time compared to the PBS group in tail suspension experiments over a 5min period (P < 0.01).
Example 6-carbohydrate preference test to assess depression levels;
anhedonia is one of the core symptoms of depression, which can be more intuitively manifested in rodents as a reduction in consumption of, and a reduction in preference for, a solution of saccharin or sucrose. Sugar water preference test mice were evaluated for anhedonia levels by comparing their drinking amounts of sucrose solution and water over 24 h.
1. Before the official test, the training was tested and C57BL/6J mice were acclimated to use two drinking bottles for 24 h. Firstly, filling tap water in two drinking bottles, and replacing the drinking bottles with 1% of sucrose solution after 12 hours;
2. after the test is started, two drinking bottles are respectively filled with tap water and 1% sucrose solution and placed on two sides of a mouse cage, and the positions of the two drinking bottles are exchanged every 12 hours, so that the mice can freely take the tap water or the sucrose solution, and the position preference is avoided;
3. after 24h, the consumption of tap water and sucrose solution was recorded and the sugar water preference rate of the mice was calculated as follows: the sugar water preference rate is [ (sucrose consumption)/(water consumption + sucrose consumption) ] × 100%. Considering that the ratio is expressed as sugar water preference when the ratio is more than 70 percent, and losing the sugar water preference when the ratio is less than 65 percent;
4. in the test, the leakage of the drinking bottle is avoided as much as possible, and the accurate reading is ensured. All tested C57BL/6J mice were housed in a single cage and provided with sufficient water and food.
Sugar water preference results as shown in figure 6, sugar water preference rates of 12, 24 and 48mg/kg T β 4 group mice increased significantly (P <0.01) 7 days after T β 4 application.
As can be seen from the above examples, the pharmaceutical formulation comprising thymosin beta 4 designed by the invention has a rapid antidepressant effect in mice, and can reverse CSDS-induced depressive-like behavior within 7 days.
Claims (10)
1. The thymosin beta 4 pharmaceutical preparation for treating depression is characterized by comprising effective dose of thymosin beta 4 and a carrier, wherein the carrier is one or two or more than two auxiliary materials, and each 100 parts by mass of the pharmaceutical preparation comprises 12-48 parts by mass of thymosin beta 4, and the balance is the auxiliary materials.
2. The thymosin beta 4 pharmaceutical preparation for treating depression according to claim 1, comprising 20-40 parts by mass of thymosin beta 4 per 100 parts by mass of the pharmaceutical preparation.
3. Thymosin beta 4 pharmaceutical preparation for the treatment of depression according to claim 1 or 2, wherein said adjuvant is phosphate buffered saline.
4. The thymosin beta 4 pharmaceutical preparation for treating depression according to claim 3, wherein said pharmaceutical preparation is a liquid preparation and contains thymosin beta 4 in an amount of 30 parts by mass per 100 parts by mass of the liquid preparation.
5. A method of preparing the pharmaceutical formulation of claim 1, comprising blending thymosin β 4 with a carrier and formulating the desired formulation.
6. Use of a pharmaceutical formulation according to claim 1 for the manufacture of a medicament for the treatment of depressive behaviour in a mammal.
7. The use of claim 6, which comprises nasally administering to the subject mammal a pharmaceutical formulation comprising thymosin β 4 in amounts of: 12-48 mg daily, and continuously administering for 7 days;
the tested mammal is obtained by screening through establishing a chronic social frustration stress model.
8. The use of claim 7, further comprising evaluating the efficacy of a pharmaceutical formulation comprising thymosin β 4 by comparing the experimental behavior of said subject mammal before and after administration;
after 7 days of continuous administration, the behavior of the subject mammal was reversed in depression induced by a model of chronic social frustration stress.
9. The use according to claim 8, wherein the test for assessing the body of the subject mammal comprises one or any two or more of social interaction test, tail suspension test and sugar water preference test.
10. The use according to any one of claims 6 to 9, wherein the subject mammal is a mouse.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010830592.5A CN111888463B (en) | 2020-08-18 | 2020-08-18 | Thymosin beta 4 medicinal preparation for treating depression, preparation method and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010830592.5A CN111888463B (en) | 2020-08-18 | 2020-08-18 | Thymosin beta 4 medicinal preparation for treating depression, preparation method and application thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN111888463A true CN111888463A (en) | 2020-11-06 |
CN111888463B CN111888463B (en) | 2021-09-21 |
Family
ID=73229001
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010830592.5A Active CN111888463B (en) | 2020-08-18 | 2020-08-18 | Thymosin beta 4 medicinal preparation for treating depression, preparation method and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111888463B (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113243338A (en) * | 2021-05-14 | 2021-08-13 | 福州大学 | Construction and evaluation method of mouse ischemic stroke model |
CN113558010A (en) * | 2021-07-19 | 2021-10-29 | 重庆师范大学 | Method for establishing zebra fish depression model and determining anti-depression activity of moraxella berbamine |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5578570A (en) * | 1993-10-07 | 1996-11-26 | The George Washington University Medical Center | Method of treating septic shock using thymosin β4 |
US20060264360A1 (en) * | 2002-04-12 | 2006-11-23 | Yale University Office Of Cooperstive Research | Anti-inflammatory and wound healing effects of lymphoid thymosin beta-4 |
CN101102784A (en) * | 2005-01-13 | 2008-01-09 | 雷金纳克斯生物制药公司 | Method of treating or preventing tissue deterioration, injury or damage due to a neuro-, muscular- or neuro-muscular-degenerative disease, or restore tissue adversely affected by said disease |
CN110430866A (en) * | 2017-03-03 | 2019-11-08 | Gtreebnt科技有限公司 | Stabilization external preparation containing extrasin beta -4 as effective component |
CN111386337A (en) * | 2017-11-24 | 2020-07-07 | Gtreebnt科技有限公司 | Composition for promoting goblet cell proliferation or mucin secretion comprising thymosin β 4 or a derivative thereof as an active ingredient |
-
2020
- 2020-08-18 CN CN202010830592.5A patent/CN111888463B/en active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5578570A (en) * | 1993-10-07 | 1996-11-26 | The George Washington University Medical Center | Method of treating septic shock using thymosin β4 |
US20060264360A1 (en) * | 2002-04-12 | 2006-11-23 | Yale University Office Of Cooperstive Research | Anti-inflammatory and wound healing effects of lymphoid thymosin beta-4 |
CN101102784A (en) * | 2005-01-13 | 2008-01-09 | 雷金纳克斯生物制药公司 | Method of treating or preventing tissue deterioration, injury or damage due to a neuro-, muscular- or neuro-muscular-degenerative disease, or restore tissue adversely affected by said disease |
CN110430866A (en) * | 2017-03-03 | 2019-11-08 | Gtreebnt科技有限公司 | Stabilization external preparation containing extrasin beta -4 as effective component |
CN111386337A (en) * | 2017-11-24 | 2020-07-07 | Gtreebnt科技有限公司 | Composition for promoting goblet cell proliferation or mucin secretion comprising thymosin β 4 or a derivative thereof as an active ingredient |
Non-Patent Citations (4)
Title |
---|
MARIE-CHRISTINE PARDON: "Anti-inflammatory potential of thymosin β4 in the central nervous system: implications for progressive neurodegenerative diseases", 《EXPERT OPINION ON BIOLOGICAL THERAPY》 * |
万娟等: "胸腺素β4参与慢性电针耐受", 《2019中国畜牧兽医学会兽医外科学分会第十届会员代表大会暨第24次学术研讨会论文集》 * |
胡晨姣: "胸腺素β4对重症胰腺炎大鼠急性肝脏损伤的保护作用", 《现代实用医学》 * |
赵荣江等: "电针对抑郁症的影响", 《临床精神医学杂志》 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113243338A (en) * | 2021-05-14 | 2021-08-13 | 福州大学 | Construction and evaluation method of mouse ischemic stroke model |
CN113558010A (en) * | 2021-07-19 | 2021-10-29 | 重庆师范大学 | Method for establishing zebra fish depression model and determining anti-depression activity of moraxella berbamine |
Also Published As
Publication number | Publication date |
---|---|
CN111888463B (en) | 2021-09-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Monzon et al. | Response to novelty after icv injection of melanin-concentrating hormone (MCH) in rats | |
CN111888463B (en) | Thymosin beta 4 medicinal preparation for treating depression, preparation method and application thereof | |
US20230330085A1 (en) | Lsd dose identification | |
Borelli et al. | Fos-like immunoreactivity in the brain associated with freezing or escape induced by inhibition of either glutamic acid decarboxylase or GABAA receptors in the dorsal periaqueductal gray | |
US7723302B2 (en) | Method of treating Parkinson's disease | |
KR20180015126A (en) | Compositions and methods for treating autism | |
KR20020068404A (en) | Drug combination for the treatment of depression and related disorders comprising mirtazapine | |
US20070154534A1 (en) | Use of secretin in the treatment of schizophrenia | |
CN110548132B (en) | Application of TGF-beta 1 protein in preparation of medicines for treating depression | |
US8741847B2 (en) | Agent and methods for reducing inflammatory markers | |
AU2010303903B2 (en) | Method of treating cravings by administration of nerve growth factor | |
WO2023102970A1 (en) | Use of parathyroid hormone in preparation of drug or health care product for treating male depression | |
Hunt et al. | Cholinergic modulation of trace conditioning trained in serial compound: A developmental analysis | |
Nakayama | Vitamin D3 and neurofibromatosis type 1 | |
RU2655763C2 (en) | Pharmaceutical composition and method for treating female sexual dysfunctions | |
WO2023202682A1 (en) | Novel target for treating or diagnosing emotional disorders or stress disorders, and application thereof | |
Jin et al. | Effect of recombinant human growth hormone add on therapy on acute stroke outcome | |
Stevens | The search for an anatomic basis of schizophrenia: Review and update | |
Apaydın | Abstracts of the 19th Turkish Neuroscience Congress, 21–23 November 2021, Online, Turkey | |
Hill et al. | Immunohistochemical and electrophysiological investigation of E/I balance alterations in animal models of frontotemporal dementia | |
US20230062537A1 (en) | Therapy of oxygen pulses for treating neurodegenerative disorders such as Parkinson Disease (PD), Alzheimer’s Disease (AD), Amiotrophic Lateral Sclerosis (ALS) or Motor Neuron Disease (MND) and other dementias, and Lymphedema, Arthritis and Depression | |
CN108785304A (en) | A kind of application of ampa receptor agonist | |
Ineichen | Nogo-A-antibodies as a potential novel therapy for relapsing and progressive Multiple Sclerosis | |
CN117205235A (en) | Microcapsule bacterial mixture for improving compulsive behavior as well as preparation method and application thereof | |
JP2002322085A (en) | Intelligent dysfunction therapeutic agent |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |